Concepedia

Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands

Dominic Thorrington, Leo van Rossum, Mirjam J. Knol, Hester E. de Melker, H. C. Rümke, Eelko Hak, Albert Jan van Hoek

PLoS ONE · 2018 · 43 citations · 16 references

DOIFull text

Open access

Abstract

Under the current assumptions, the best value for money is the use of PPV23 for elderly, with a single dose or at five year increment between age 60 to age 70.

References

16

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

Marc J. M. Bonten, Susanne M. Huijts, Marieke Bolkenbaas et al. · New England Journal of Medicine · 2015 · 1.2K citations · Full text

New perspectives on community-acquired pneumonia in 388 406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality

Santiago Ewig, Norbert Birkner, Élise Schaefer et al. · Thorax · 2009 · 407 citations · Full text

Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales

Nick Andrews, Pauline A. Waight, Robert C. George et al. · Vaccine · 2012 · 237 citations

, , +8

Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands

Marie‐Josée J. Mangen, Mark H. Rozenbaum, Susanne M. Huijts et al. · European Respiratory Journal · 2015 · 135 citations · Full text

Descriptive Epidemiology of Somatising Tendency: Findings from the CUPID Study

Sergio Vargas-Prada, David Coggon, Georgia Ntani et al. · PLoS ONE · 2016 · 106 citations · Full text